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GENERAL INTRODUCTION 
 
Vertebrate oocytes are arrested at prophase of meiosis I and undergo 
maturation after hormonal stimulation (Kishimoto, 2003; Sagata, 1996). The 
mature oocytes are rearrested at metaphase of meiosis II until fertilization. The 
metaphase-II arrest is characterized by high kinase activity of Cdk1-cyclin B 
complex, maturation promoting factor MPF, that prevents parthenogenetic 
activation (Perry and Verlhac, 2008; Tunquist and Maller, 2003).  
Emi2 is known to be a direct inhibitor of the anaphase-promoting 
complex/cyclosome (APC/C) required for degradation of cyclin B, and to cause 
metaphase-II arrest (Madgwick et al., 2006; Schmidt et al., 2005; Shoji et al., 
2006; Tung et al., 2005). In Xenopus, Mos-MAPK pathway 
(Mos-Mek1/2-Erk1/2-Rsk1/2/3) is involved in metaphase-II arrest through 
phosphorylation of Emi2 (Inoue et al., 2007; Nishiyama et al., 2007). Rsks 
possess the ability to phosphorylate four Ser/Thr residues of Emi2 at positions 
S335, T336, S342, and S344. Multiple phosphorylation of Emi2 is required for 
its stability and inhibitory binding to the APC/C, thereby promoting the 
metaphase-II arrest. 
In mice, other kinase pathways may be involved in phosphorylation of 
EMI2, because the oocytes lacking three RSKs, RSK1, RSK2, and RSK3, 
exhibit the normal metaphase-II arrest (Dumont et al., 2005). Moreover, 
inhibition of MEK1/2 synthesis by siRNA has little on metaphase-II arrest (Yu et 
al., 2007). In this study, I examined whether MSK1 and p38 play a key role in 
the metaphase-II arrest through phosphorylation of EMI2.   
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CHAPTER I 
 
 
Possible involvement of mitogen- and stress-activated protein kinase 1, 
MSK1, in metaphase-II arrest through phosphorylation of EMI2 in mouse 
oocytes. 
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SUMMARY 
 
Ovulated oocytes are arrested at the metaphase of second meiotic division. 
The metaphase-II arrest in Xenopus oocytes is regulated by RSKs located 
downstream of the Mos–MAPK pathway. In mice, other kinase(s) besides RSKs 
may be responsible for the metaphase-II arrest, because 
RSK1/RSK2/RSK3-triple knockout mice exhibit no obvious phenotype. Here, I 
show the subcellular localization and possible role of mitogen- and 
stress-activated kinase 1, MSK1 known as another downstream kinase of the 
Mos–MAPK pathway, in the mouse oocyte. Immunostaining analysis indicated 
that MSK1 is present in the germinal vesicle (GV) and cytoplasm of oocytes at 
the GV and metaphase-II stages, respectively. An active, phosphorylated form of 
MSK1 was predominantly localized to the metaphase-II spindle. The inhibition 
of the MSK1 activity failed to maintain the sister chromatid alignment within 
the metaphase-II plate. Importantly, MSK1 exhibited the ability to 
phosphorylate four Ser/Thr residues of meiotic cell-cycle regulator EMI2. The 
phosphorylation was required for up-regulation of the EMI2 activity in the 
oocytes. These results suggest that mouse MSK1 may play a key role in the 
metaphase-II arrest through phosphorylation of EMI2.  
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INTRODUCTION 
 
The meiotic cell cycle consists of two successive divisions: meiosis I and 
meiosis II. Germinal vesicle (GV)-stage oocytes in many vertebrates are arrested 
first at the prophase of meiosis I and undergo maturation after hormonal 
stimulation (Kishimoto, 2003; Sagata, 1996). The mature oocytes are re-arrested 
by cytostatic factor CSF at the metaphase of meiosis II (Masui and Markert, 
1971). The metaphase-II arrest of the oocytes is regulated by the Mos–MAPK 
pathway that maintains the kinase activity of CDK1 – cyclin B complex 
(maturation promoting factor, MPF) at an elevated level (Perry and Verlhac, 
2008; Tunquist and Maller, 2003). Following fertilization the kinase activity of 
MPF is reduced owing to degradation of cyclin B, which leads to release from 
the metaphase-II arrest of the oocytes.  
F-box protein 43 (EMI2), a key component of CSF, is known to inhibit 
anaphase-promoting complex/cyclosome (APC/C) required for degradation of 
cyclin B, and to cause the metaphase-II arrest in the mouse and Xenopus oocytes 
(Madgwick et al., 2006; Schmidt et al., 2005; Shoji et al., 2006; Tung et al., 
2005). Both stability and activity of Xenopus Emi2 in the metaphase-II arrest are 
up-regulated by RSKs, 90-kDa ribosomal S6 kinases, located immediately 
downstream of ERK1/2 MAPK (Bhatt and Ferrell, 2000; Gross et al., 2000; 
Inoue et al., 2007; Nishiyama et al., 2007). RSKs possess the ability to 
phosphorylate four Ser/Thr residues of Xenopus Emi2 at positions S335, T336, 
S342, and S344. Although RSKs are identified as the ERK1/2 substrates (Kalab 
et al., 1996), the mouse oocytes lacking three RSKs, RSK1, RSK2, and RSK3, 
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exhibit the normal metaphase-II arrest (Dumont et al., 2005). Thus, these 
findings raise the possibility that other kinase(s) instead of RSKs may 
participate in phosphorylation of EMI2 in the mouse oocytes (Inoue et al., 2007; 
Suzuki et al., 2010).  
Mitogen- and stress-activated protein kinases, MSK1 and MSK2 
(RPS6KA5 and RPS6KA4, respectively), are activated by ERK1/2 and/or p38 
MAPK following cellular stimulation in somatic cells (Deak et al., 1998; Pearce 
et al., 2010; Wiggin et al., 2002). MSKs resemble RSKs because these proteins 
belong to the AGC kinase subfamily, and have two kinase domains connected by 
a regulatory linker region. However, the presence and function of MSKs in the 
mouse oocytes still remain uncertain. In this study, I have focused on the 
subcellular localization and function of MSK1 in the mouse oocytes. My data 
suggest that MSK1 may play a key role in phosphorylation of EMI2 to maintain 
the metaphase-II arrest. 
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MATERIALS AND METHODS 
 
Plasmids 
 
DNA fragments encoding EMI2 (GenBank ID: NP_001074772.1), MSK1 
(GenBank ID: AAQ24165.1), and CREB (GenBank ID: NP_034082.1) were 
amplified by PCR using a mouse ovary or testis cDNA library as a template. The 
following sets of oligonucleotides were used as primers:  
5′-GGGCGGCCGCGGATGGACTCCTCTGCTGTC-3′ and 
5′-GGCTCGAGTCAGAGGCGTTTTAAGTTCCGC-3′ for EMI2; 
5′-GCCTCGAGAGGGTGAAGATGGAGGG-3′ and 
5′-GCTCTAGAACATACCTCAGGCACATG-3′ for MSK1; 
5′-GCGAATTCATGACCATGGAATCTGGAGC-3′ and 
5′-GCCTCGAGAACTTAAATCCCAAATTAATC-3′ for CREB. The amplified 
fragments were introduced into pcDNA3/FLAG-HA or pGEX-4T-1. To prepare 
pET-32a/EMI2, pGEX-4T-1/EMI2, and pGEX-4T-1/EMI2 plasmids containing 
the EMI2 sequences at residues 3–400, 3–400, and 204–383, respectively, DNA 
fragments were PCR-amplified from pcDNA3/FLAG-HA/EMI2 as a template, 
and introduced into the vectors. pcDNA3.1-poly(A)/FLAG-HA/EMI2 plasmid 
was prepared by introducing the KpnI/BamHI fragment of 
pcDNA3/FLAG-HA/EMI2 into pcDNA3.1-poly(A), as described previously 
(Yamazaki et al., 2007). In vitro site-directed mutagenesis was carried out 
according to the manufacturer′s protocol (Agilent Technology, Santa Clara, CA).  
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Reverse transcription-PCR 
 
First-strand cDNA was synthesized from total RNA of mouse oocytes using 
a SuperScript™ III First-Strand Synthesis system (Invitrogen, Carlsbad, CA). 
DNA was amplified by PCR using an Advantage cDNA Polymerase Mix 
(Clontech, Mountain View, CA). The following sets of oligonucleotides were 
used as primers: 5′-GCTACTAACTGGAGCATCTCCTTTC-3′ and 
5′-TCAAGAGACGCTGAAGTAGGTCTT-3′ for MSK1; 
5′-GAGATGTTCACTCACCTCTACCAG-3′ and 
5′-TGAGTCAAGTAAGACGTTCTCCAG-3′ for MSK2; 
5′-AAAAGCTTGGCGCTTTTGACTCAGGA-3′ and 
5′-GGAATTCAAGTCAGTGTACAGGCCAG-3′ for ACTB (β-actin). The 
reaction program consisted of 40 cycles of 94 °C for 30 s, 62 °C for 30 s, and 
68 °C for 45 s.  
 
Antibodies 
 
His-tagged recombinant protein of mouse EMI2 containing the amino acid 
sequence at positions 3–400 was produced in Escherichia coli BL21 (DE3), as 
described previously (Kim et al., 2005; Shoji et al., 2006). The recombinant 
protein was purified on a Ni-NTA His column (Novagen, Madison, WI), 
emulsified with Freund's complete (Difco Laboratories, Detroit, MI) or 
incomplete adjuvant (Wako, Osaka, Japan), and injected into female New 
Zealand White rabbits (SLC, Shizuoka, Japan). Anti-EMI2 antibody was 
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purified on a Sepharose 4B column previously coupled with glutathione 
S-transferase (GST)-tagged EMI2, as described previously (Baba et al., 1994). 
Anti-cyclin B1, anti-phosphorylated MSK1, and anti-phosphorylated ERK1/2 
antibodies were purchased from Cell Signaling Technology (Danvers, MA), and 
anti-ACTB and anti-TUBB1 (β-tubulin) antibodies were from Sigma-Aldrich 
(Saint Louis,MO). Anti-MSK1 monoclonal (Cell Signaling Technology) and 
polyclonal (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were mainly 
used for immunoblot and immunostaining analysis, respectively. Horseradish 
peroxidase-conjugated antibodies against mouse, rat, or rabbit IgG were 
purchased from Jackson Immunoresearch Laboratories (West Grove, PA). Alexa 
Fluor 488- or 568-conjugated antibodies against rat, mouse or rabbit IgG were 
purchased from Molecular Probes (Eugene, OR). All animal experiments were 
performed ethically, and experimentation was in accord with the Guide for the 
Care and Use of Laboratory Animals at University of Tsukuba. 
 
Oocyte collection and microinjection 
 
The GV-stage oocytes were collected from ovaries of 8- to 9-week-old ICR 
mice (SLC) 46–48 h after intraperitoneal injection of pregnant mare's serum 
gonadotropin (Aska Pharmaceutical, Tokyo, Japan). The oocytes were put in a 
drop of KSOM (Lawitts and Biggers, 1993) containing 10 mM HEPES and 0.24 
mM N
6, 2′-O-dibutyryladenosine 3′:5′-cyclic monophosphate, (dbcAMP; 
Sigma-Aldrich). cRNAs (40 ng/μl) and 4 mM MSK1 morpholino 
oligonucleotide (MO; CCTCCCCCTCCATCTTCACCCTCTT, Gene Tools, 
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Philomath, OR) were microinjected into the oocytes using a Femtojet constant 
flow system (Eppendorf, Hamburg, Germany). The oocytes were cultured in 
TYH medium (Toyoda et al., 1971) containing bovine serum albumin (BSA; 4 
mg/ml).  
 
Immunoblot analysis 
  
Proteins were separated by SDS-PAGE and transferred onto Immobilon-P 
polyvinylidene difluoride membranes (Millipore, Bedford, MA). The blots were 
blocked with 20 mM Tris/HCl, pH 7.5, containing 5% skim milk or BSA, 0.1% 
Tween-20, and 0.15 M NaCl, incubated with primary antibodies, and then 
treated with secondary antibodies conjugated with horseradish peroxidase. The 
immunoreactive proteins were visualized by using an ECL detection system (GE 
Healthcare, Piscataway, NJ).  
 
Immunostaining analysis  
 
Mouse ovarian and oviductal tissues were fixed in 4% paraformaldehyde at 
4 °C overnight, embedded in paraffin, and sliced into 5-μm sections. The 
sections were treated with 10 mM Tris/HCl, pH 8.0, containing 1 μg/ml 
proteinase K, and 1 mM EDTA at 37 °C for 30 min, boiled in 10 mM trisodium 
citrate dihydrate and 10 mM citric acid monohydrate for 5 min, and then treated 
with phosphate buffered saline, PBS, containing 1% Triton X-100 at 4 °C for 20 
min. The sections were blocked with PBS containing 3% goat serum and 0.05% 
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Tween-20 at room temperature for 60 min, incubated with primary antibodies, 
reacted with secondary antibodies conjugated with Alexa Fluor 488 or 568 at 
room temperature for 60 min, counterstained with Hoechst 33342, and then 
viewed under an IX71 fluorescence microscope (Olympus, Tokyo, Japan), as 
described previously (Kimura et al., 2009).  
 
RNA synthesis in vitro 
 
RNAs were synthesized by T7 polymerase using a RiboMAX large scale 
RNA production system-T7 kit (Promega, Madison, WI). The RNAs were 
treated with RQ1 RNase-free DNase (Promega) at 37 °C for 20 min, extracted 
with phenol/chloroform, precipitated with ethanol, dissolved in 10 mM Tris/HCl, 
pH 7.4, containing 0.1 mM EDTA, applied to MicroSpin G-25 columns (GE 
Healthcare), and stored at −80 °C.  
 
Cell culture and immunoprecipitation 
 
HEK293T cells were cultured in Dulbecco's modified Eagle's medium 
(Wako) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 0.1 
mg/ml streptomycin at 37 °C under 5% CO
2
 in air. Cells were transfected with 
expression plasmid encoding FLAG–HA-tagged MSK1 using a PerFectin 
transfection reagent (Genlantis, San Diego, CA). After 48-h incubation, cells 
were cultured in serum-free medium for 24 h, and then treated with 1 μM TPA, 
12-O-tetradecanoylphorbol 13-acetate (LC Laboratories, Woburn, MA) for 60 
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min. Cells were lysed with 25 mM Tris/HCl, pH 7.5, containing 0.15 M NaCl, 
0.1% SDS, 1% NP-40, 1 mM EDTA, 1 μg/ml aprotinin, 1 μg/ml pepstatin, 1 
μg/ml leupeptin, 50 μg/ml PMSF, 1 mM DTT, 20 mM NaF, and 0.5 mM 
Na3VO4. The cell lysates containing recombinant MSK1 were subjected to 
immunoprecipitation using anti-FLAG M2 agarose beads (Sigma-Aldrich). The 
purity of the recombinant protein was evaluated by SDS-PAGE (Fig. 1).  
 
In vitro kinase assay  
 
The assays were carried out in 10 mM Tris/HCl, pH 7.5, containing 10 mM 
MgCl2, 0.1 mM DTT, 0.1 mM Na3VO4, 50 μM NaF, 10 μM ATP, and 2.5 μCi 
[γ-32P]ATP (MP Biomedicals, Santa Ana, CA). GST-tagged proteins (1 μg) were 
incubated with MSK1 (0.1 μg) purified from HEK293T cells in the above buffer 
at 30 °C for 15 min, and subjected to SDS-PAGE. Proteins were visualized by 
Coomassie briliant blue (CBB) staining and autoradiography.  
 
Statistical analysis  
 
Data are presented as mean values ± S.E. (n = 3). The Student's t-test was 
used for statistical analysis; significance was assumed for p<0.05. 
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Fig. 1. Purification of MSK1 and RSK1 from HEK293T cells. HEK293T cells were transfected with 
expression plasmids, pcDNA3/FLAG-HA/MSK1. Cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin 
at 37 ºC for 48 h under 5% CO2 in air, incubated in the serum-free medium for 24 h, and then treated 
with 1 μM TPA for 60 min. The cell lysates were subjected to immunoprecipitaiton using 
anti-FLAG M2 agarose beads. Proteins in the immunoprecipitate were separated by 
SDS-PAGE and stained with CBB. As a control, cells were transfected with only 
pcDNA3/FLAG-HA vector (None). 
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RESULTS 
 
Expression of Msk1 and Msk2 in mouse oocytes 
 
Ubiquitous expression of Msk1 and Msk2 has been reported in mouse 
tissues (Deak et al., 1998). I initially carried out RT-PCR to examine expression 
of these two genes in the mouse oocytes (Fig. 2A). Msk1 was expressed in the 
oocytes at the GV stage, and the metaphase II-stage oocytes still contained Msk1 
mRNA. No Msk2 expression was found in the oocytes at both stages. As 
expected, immunoblot analysis indicated the presence of MSK1 in the GV- and 
metaphase-II oocytes (Fig. 2B). Activation of human MSK1 requires 
phosphorylation by ERK1/2 at S360, T581 and T700 (S359, T645 and T824 in 
mouse MSK1, respectively) in somatic cells (Brami-Cherrier et al., 2009). In 
this study, I used anti-phosphorylated MSK1 antibody that recognized 
phosphorylated T581 and T645 of human and mouse MSK1, respectively. 
Interestingly, the phosphorylated form of MSK1 was found only in the 
metaphase-II oocytes (Fig. 2B). These data suggest that the mouse oocytes 
contain MSK1 that is activated by phosphorylation after the GV stage during 
oocyte maturation.  
 
Subcellular localization of phosphorylated MSK1 
 
When immunostaining analysis of ovarian and oviductal sections was 
carried out, MSK1 was widely distributed in granulosa and cumulus cells and   
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Fig. 2. Expression and localization of mouse MSK1 and MSK2. (A) RT-PCR analysis. Total RNAs 
were prepared from the GV- and metaphase II (MII)-stage oocytes, ovary, and brain of mice, and 
subjected to RT-PCR. (B) Immunoblot analysis. Whole protein extracts of GV- and MII-stage oocytes 
(50 cells/lane) were analyzed using anti-MSK1, anti-phosphorylated MSK1 (pMSK1), and β-tubulin. 
Mouse testicular and brain extracts (4 μg/lane) were also analyzed. (C) Immunostaining analysis. 
Mouse ovarian and oviductal sections containing the GV- and MII-stage oocytes, respectively, were 
probed by using anti-ZP2 (green) and anti-MSK1 (red) antibodies, and counterstained with Hoechst 
33342 (blue). An arrow indicates the GV. Scale bar = 100 μm. (D) Presence of pMSK1 in the MII 
oocytes. Sections were probed by using anti-ZP2 (green) and anti-pMSK1 antibodies (red), and 
counterstained with Hoechst 33342. Note that pMSK1 is present only in the MII oocytes. (E) 
Localization of pMSK1 in the bipolar spindle. The MII oocytes were stained with anti-β-tubulin 
(green) and anti-MSK1 or anti-pMSK1 (red) antibodies, and counterstained with Hoechst 33342.  
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the oocytes at the GV and metaphase-II stages (Fig. 2C). In the GV and 
metaphase-II oocytes, MSK1 was predominantly present in the GV and 
cytoplasm, respectively. No significant signal of phosphorylated MSK1 was 
found in the GV-stage oocytes, and granulosa and cumulus cells (Fig. 2D). 
Importantly, phosphorylated MSK1was distributed throughout the cytoplasm of 
the metaphase II-stage oocytes, and was noticeably enriched within the 
metaphase-II plate. As compared with unphosphorylated MSK1, phosphorylated 
MSK1 was abundantly co-localized with β-tubulin in the bipolar metaphase-II 
spindle (Fig. 2E). Thus, phosphorylated MSK1 may function in bipolar spindle 
formation. 
 
Phosphorylation of MSK1 through Mos–MAPK pathway 
 
I next examined whether phosphorylation of MSK1 in the metaphase-II 
oocytes is dependent on the Mos–MAPK pathway. The GV-stage oocytes 
underwent spontaneous maturation for 24 h in the presence of U0126, a potent 
inhibitor specific for MEK1/2 located immediately upstream of ERK1/2 in the 
Mos–MAPK pathway (Yu et al., 2007). Approximately 70% of total oocytes 
resumed the meiotic cell cycle in the absence of the inhibitor, and were arrested 
at the metaphase-II stage (Fig. 3A). In the presence of U0126, most oocytes 
(71%) were maintained at the GV stage, and no metaphase-II oocyte was found. 
As described previously (Tong et al., 2003), approximately 14% of the oocytes 
extruded large polar bodies and formed no spindles (Fig. 3A and B). Moreover, 
the abnormal oocytes containing large polar bodies possessed no phosphorylated  
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Fig. 3. Phosphorylation of MSK1 through Mos–MAPK pathway. (A) Effect of U0126 on oocyte 
maturation. The GV-stage oocytes were cultured for 24 h with (+) or without (−) a MEK1/2-specific 
inhibitor, U0126 (0.1 mM). After incubation, the ratio of oocytes at the GV, metaphase-II (MII), large 
polar body (LPB), and other stages was counted. Numbers in parentheses indicate those of the oocytes 
examined. (B) Immunostaining analysis. The GV-stage oocytes were cultured in the absence (−) or 
presence (+) of 0.1 mM U0126 for 24 h, and stained with anti-β-tubulin (green) and 
anti-phosphorylated MSK1 (pMSK1, red) antibodies, and Hoechst 33342 (blue). (C) Immunoblot 
analysis. The LPB oocytes were prepared by incubation of the GV-stage oocytes in the presence (+) of 
60 μM U0126 for 24 h. The oocytes at the GV and MII stages were directly subjected to immunoblot 
analysis. Proteins (50 oocytes/lane) were analyzed using anti-phosphorylated ERK1/2 (pERK1/2), 
anti-pMSK1, and anti-β-tubulin antibodies.  
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forms of ERK1/2 and MSK1 (Fig. 3C). These results suggest that MSK1 is 
phosphorylated by the Mos–MAPK pathway during oocyte maturation. 
 
Involvement of MSK1 in metaphase-II arrest 
 
To clarify the role of MSK1 in the metaphase-II arrest further, I 
microinjected an Msk1 MO into the oocytes at the GV stage, which were 
incubated for 12 h in the presence of dbcAMP and then matured for 24 h in the 
absence of dbcAMP (Fig. 4). The Msk1 MO only partially (approximately 40%) 
prevented the accumulation of MSK1 protein in the metaphase II-stage oocytes, 
and failed to affect the metaphase-II arrest. I also examined effects of two 
chemical inhibitors, H89 and Ro31-8220 on release from the metaphase-II arrest 
(Fig. 5). Although H89 and Ro31-8220 are commonly used to inhibit the 
activities of PKA and PKC, respectively, these two chemicals are also known to 
interfere with the MSK1 activity (Espino et al., 2006; Kawaguchi et al., 2009). 
When the metaphase-II oocytes were incubated with or without H89 for 6 h, the 
metaphase-II arrest was 15 and 93% released by the presence of 30 and 60 μM 
H89, respectively (Fig. 5A). In the case of 5 μM Ro31-8220, the oocytes were 
97% released from the metaphase-II arrest (Fig. 5B). I observed chromosome 
segregation and abnormal pronuclear formation 2 and 4 h after addition of 60 
μM H89, respectively (Fig. 5C). In the H89-treated oocytes, phosphorylated 
MSK1 was spread throughout the cytoplasm, owing to the loss of bipolar 
metaphase-II spindle (Fig. 6). Moreover, immunoblot analysis revealed that 
cyclin B1 is dramatically degraded 2 h after incubation in the presence of 60 μM   
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Fig. 4. Msk1 knockdown by morpholino oligonucleotide (MO) injection. (A) Microinjection of Msk1 
MO. Mouse oocytes at the germinal vesicle (GV) stage were microinjected with 4 mM Msk1 MO or 
negative control MO using a Femtojet constant flow system, treated with dbcAMP for 12 h, incubated 
in the absence of dbcAMP for 24 h, and then stained with anti-phosphorylated MSK1 (pMSK1, red) 
antibody. Fluorescence intensities of the whole oocytes were measured. Data are presented as mean 
values ± S.E. (n = 3; p = 0.06). (B) Ratio of Msk1 MO-injected oocytes. After incubation, the oocytes 
at the GV, metaphase-I (MI), metaphase-II (MII), and other stages were counted. Numbers in 
parentheses indicate those of the oocytes examined. 
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Fig. 5. Involvement of MSK1 in the metaphase-II arrest. (A) Release from the metaphase-II (MII) 
arrest by H89. The MII oocytes were incubated with or without MSK1 inhibitor H89 (0, 30, and 60 
μM) for 6 h. The numbers in parentheses indicate those of the MII oocytes examined. *p<0.05. (B) 
Release from the MII arrest by Ro31-8220. The MII oocytes were incubated with or without MSK 
inhibitor Ro31-8220 (0, 1, and 5 μM). (C) Immunostaining analysis. The MII oocytes were incubated 
in the presence of H89 (60 μM) for 2 and 4 h, and then stained with Hoechst 33342 (blue) and 
anti-β-tubulin antibody (green). Scale bar = 50 μm. (D) Immunoblot analysis. The MII oocytes were 
incubated in the presence of H89 (60 μM) for 0, 2, and 4 h, and proteins (30 oocytes/lane) were 
analyzed using antibodies against phosphorylated ERK1/2 (pERK1/2), anti-phosphorylated MSK1 
(pMSK1), EMI2, cyclin B1, and β-actin.  
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Fig. 6. Immunostaining of the metaphase-II oocytes treated with H89. The metaphase-II oocytes were 
incubated in the absence (-) or presence (+) of 60 μM H89 for 4 h, and stained with anti-β-tubulin 
(green) and anti-phosphorylated MSK1 (pMSK1, red) antibodies, and with Hoechst 33342 (blue). 
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H89 (Fig. 5D). The levels of phosphorylated ERK1/2, phosphorylated MSK1, 
and EMI2 remained relatively constant throughout incubation. These results 
suggest that the inhibition of the kinase activity of phosphorylated MSK1 by 
H89 may result in the failure of EMI2 phosphorylation/activation, leading to the 
degradation of cyclin B1.  
 
Phosphorylation of EMI2 by MSK1 
 
To ascertain the possibility that MSK1 directly phosphorylates EMI2 to 
maintain the metaphase-II arrest, I carried out kinase assays in vitro using 
GST-fused proteins (Fig. 7). In Xenopus, four Ser/Thr residues of Emi2 at 
positions S335, T336, S342, and S344 are phosphorylated by RSKs (Inoue et al., 
2007; Nishiyama et al., 2007). This phosphorylation is required for 
up-regulation of the stability and activity of Emi2 in the oocytes. Since these 
four residues of Xenopus Emi2 are conserved in the mouse, human, and 
zebrafish counterparts (Fig. 7A), it is assumed that mouse MSK1 as well as 
Xenopus RSKs is capable of phosphorylating the same Ser/Thr residues of EMI2. 
I thus prepared phosphorylated MSK1 from HEK293T cells that had been 
cultured with TPA (Figs. 1 and 8), and then carried out in vitro kinase assays 
using the purified protein. Both EMI2 and transcription factor CREB (Deak et 
al., 1998) as a positive control were efficiently phosphorylated by MSK1 (Fig. 
7B). Phosphorylation of EMI2 by MSK1 was 34 and 87% inhibited by addition  
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Fig. 7. Phosphorylation of EMI2 by MSK1. (A) Alignment of the amino acid sequences of EMI2 
among mouse, human, Xenopus, and zebrafish. Gray boxes and asterisks indicate the conserved 
residues and possible phosphorylation sites by Xenopus RSKs, respectively. The sequence of an 
EMI2/4A mutant is also aligned. (B) In vitro kinase assay. GST-tagged EMI2 (1 μg) was incubated 
with (+) or without (−) purified MSK1 (0.1 μg) in the presence of [γ-32P]ATP, separated by 
SDS-PAGE, and analyzed by autoradiography and CBB staining. GST alone and GST-tagged CREB 
were used as negative and positive controls, respectively. An asterisk indicates background proteins. 
(C and D) Inhibition of MSK1 kinase activity. Purified MSK1 was incubated with GST-tagged EMI2 
in the absence and presence (0, 0.2, and 2 μM each) of H89 (C) or of Ro31-8220 (D). *p<0.05. (E) 
Phosphorylation of EMI2/4A by MSK1. Wild-type (WT) EMI2 and EMI2/4A were incubated with (+) 
or without (−) MSK1. *p<0.05. 
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Fig. 8. Up-regulation of the MSK1 activity by TPA. Immunoblot analysis of TPA-treated cell lysates. 
HEK293T cells were transfected with pcDNA3/FLAG-HA only (-) or pcDNA3/FLAG-HA/MSK1 (+), 
as described in Fig. 1, and then treated without (0 min) or with 1 μM TPA for 20, 40, and 60 min. 
Proteins in of cell lysates were analyzed by immunoblotting using antibody against phosphorylated 
ERK1/2 (pERK1/2), MSK1, phosphorylated MSK1 (pMSK1), or β-tubulin.  
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of 0.2 and 2 μM H89 (74 and 87% for 0.2 and 2 μM Ro31-8220), respectively 
(Fig. 7C and D). I further examined whether MSK1 phosphorylates four Ser/Thr 
residues of EMI2 at S326, T327, S333, and S335 (Fig. 7E). A GST-tagged EMI2 
mutant protein, termed EMI2/4A, in which these four Ser/Thr residues were all 
substituted with Ala (Fig. 7A), was analyzed by in vitro kinase assays. The 
EMI2/4A mutant was barely phosphorylated by MSK1 as compared to wild-type 
EMI2 (Fig. 7E). Thus, MSK1 possesses the ability to phosphorylate S326, T327, 
S333, and S335 on the EMI2 molecule.  
 
Up-regulation of EMI2 activity by S326, T327, S333, and S335 phosphorylation  
 
Ala substitutions of S335 and T336 or T336, S342, and S344 in Xenopus 
Emi2 have been demonstrated to result in protein degradation dependent of E3 
ubiquitin ligase SCF β-TrCP during oocyte maturation (Inoue et al., 2007; 
Nishiyama et al., 2007). SCF β-TrCP recognizes the phosphodegron sequence, 
Asp-Ser-Ala-Phe-His-Ser, of Xenopus Emi2 at residues 283–313. Because the 
Xenopus phosphodegron sequence is conserved in the mouse EMI2 sequence, 
Asp-Ser-Gly-Phe-Cys-Ser, at residues 274–279, I constructed expression 
plasmids encoding an EMI2/DSG mutant carrying Ala substitutions at S275 and 
S279, and an EMI2/DSG/4A mutant. To examine the inhibitory activities of 
these two EMI2 mutants toward APC/C in an experimental model system 
(Suzuki et al., 2010), I microinjected synthetic RNA encoding HA-tagged 
EMI2/DSG or EMI2/DSG/4A mutant into the GV-stage oocytes containing a 
negligibly small amount of endogenous EMI2 (Madgwick et al., 2006; Shoji et 
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al., 2006). The RNA-injected oocytes were cultured in the presence of dbcAMP 
for 2 h, and then underwent spontaneous maturation in the absence of dbcAMP 
for 20 h (Fig. 9A). Exogenously expressed EMI2 is known to induce the 
metaphase-I arrest under these conditions (Suzuki et al., 2010). Immunostaining 
analysis using anti-HA antibody verified production of EMI2/DSG and 
EMI2/DSG/4A mutant proteins in the oocytes after the 20-h incubation (Fig. 9B). 
Importantly, the oocytes containing the EMI2/DSG protein were mostly (84%) 
arrested at the metaphase-I stage, whereas a significantly low level (43%) of the 
metaphase-I arrest was found in the oocytes containing the EMI2/DSG/4A 
protein (Fig. 9C). In contrast, 40% of total EMI2/DSG/4A-containing oocytes 
underwent meiotic maturation and progressed to the metaphase-II stage. Since 
endogenously produced MSK1 was phosphorylated in the 
EMI2/DSG-containing oocytes arrested at the metaphase-I stage (Fig. 10), the 
phosphorylation of EMI2 at S326, T327, S333, and S335 is probably required 
for the metaphase-I arrest of the oocytes. Thus, MSK1 may be involved in the 
metaphase-II arrest through phosphorylation of EMI2 in the mouse. On the basis 
of the data obtained, I propose a schematic model for the metaphase-II arrest in 
the mouse oocyte (Fig. 9D).  
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Fig. 9. EMI2 activity is up-regulated by phosphorylation at S326, T327, S333 and S335. (A) 
Experimental protocol for expression of EMI2/DSG and EMI/DSG/4A mutants. The GV-stage oocytes 
were microinjected with polyadenylated RNA encoding HA-tagged EMI2/DSG and EMI2/DSG/4A 
(termed DSG and DSG/4A, respectively), and incubated in the presence of dbcAMP for 2 h. After 
incubation in the absence of dbcAMP for 20 h, the oocytes at different maturation stages were counted. 
MI, metaphase I; MII, metaphase II. Note that the oocytes contain a negligibly small amount of 
endogenous EMI2 until the MI/MII transition. (B) Immunostaining analysis. The oocytes were 
immunostained with anti-HA antibody (red). Fluorescence intensities of the oocytes expressing 
HA-tagged DSG or DSG/4A (15 cells each) were measured. Arrows indicate polar bodies. Scale bar = 
100 μm. (C) Ratio of oocytes at GV, MI, and MII stages. Numbers in parentheses indicate those of the 
oocytes examined. (D) Schematic model for the MII arrest in the mouse oocytes. RSKs regulate the 
Emi2 activity in the Xenopus oocytes. In the mouse oocytes, the EMI2 activity may be regulated 
predominantly by MSK1, although participation of RSKs cannot be neglected completely. 
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Fig. 10. Phosphorylation of MSK1 in metaphase-I arrested oocytes. The germinal vesicle-stage 
oocytes were microinjected with polyadenylated RNA encoding HA-tagged EMI2/DSG, and 
incubated in the presence of dbcAMP for 2 h. After incubation in the absence of dbcAMP for 20 h, the 
oocytes were stained with anti-β-tubulin (green) and anti-phosphorylated MSK1 (pMSK1, red) 
antibodies, and counterstained with Hoechst 33342 (blue). 
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DISCUSSION 
 
This study describes the subcellular localization and possible role of MSK1 
in the metaphase-II arrest of the mouse oocyte. Two MSKs, MSK1 and MSK2, 
are ubiquitously expressed and predominantly localized in the cell nucleus 
(Deak et al., 1998). Of these two MSKs, only MSK1 is present in the GV and 
cytoplasm of oocytes at the GV and metaphase-II stages, respectively (Fig. 2). 
MSK1 is changed to the active form by Ser/Thr phosphorylation after the GV 
stage, and the phosphorylated protein is enriched in the bipolar spindle in the 
metaphase-I/II oocytes (Figs. 2 and 10). In addition, phosphorylated MSK1 is 
capable of phosphorylating four Ser/Thr residues of EMI2 (Fig. 7), which is 
required for the CSF arrest (Fig. 9). These findings suggest that MSK1 may play 
a key role in the metaphase-II arrest of oocytes through phosphorylation of 
EMI2 in the mouse. It is important to note that consistent with previous data 
regarding the localization of ERK1/2 (Fan et al., 2009; Sasseville et al., 2010), 
MSK1 is also localized in granulosa and cumulus cells (Fig. 2). This observation 
implies a functional role of MSK1 in these cells.  
Phosphorylated MSK1 is abundantly present in the bipolar spindle of 
metaphase-I/II oocytes (Figs. 2 and 10), as described above. ERK1/2 are thought 
to phosphorylate MSK1 as a target protein in somatic cells (Deak et al., 1998). 
In the mouse oocytes, phosphorylation of ERK1/2 is directly catalyzed by 
MEK1/2 that are activated by Mos (Verlhac et al., 1996), as shown in Fig. 9D. 
Indeed, both the inhibition of ERK1/2 activation by the MEK inhibitor U0126 
(Tong et al., 2003) and the deletion of Mos (Colledge et al., 1994; Hashimoto et 
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al., 1994) have been reported to induce to release the metaphase-II arrest. Since 
ERK1/2 are activated by MEK1/2 immediately after GV breakdown in the 
mouse oocytes (Tsurumi et al., 2004), activation of MSK1 probably takes place 
successively through phosphorylation by ERK1/2 (Fig. 3). Phosphorylated 
MSK1 may then act on activation of EMI2 present in the bipolar spindle (Suzuki 
et al., 2010). It is also suggested that phosphorylated MSK1 may function in 
phosphorylation of unknown target protein(s) localized in the oocyte spindle. 
Indeed, the loss of active ERK1/2 has been reported to result in the abnormal 
shape of bipolar spindle, because of no activation of the ERK1/2 substrates, 
including MISS and DOC1R (Lefebvre et al., 2002; Terret et al., 2003).  
MO is conventionally utilized to inhibit production of target proteins in the 
mouse oocytes; however, accumulation of some proteins present in the GV-stage 
oocytes is not entirely prevented by MO (Chang et al., 2009; Yuan et al., 2010). 
In the present study, despite injection of Msk1 MO into the GV-stage oocytes, 
the Msk1 knockdown oocytes still contained a relatively large amount of MSK1 
after meiotic resumption, and failed to affect the meiotic arrest at the 
metaphase-II stage (Fig. 4). This phenotype may be due to the possibility that 
MSK1 accumulation in the GV-stage oocytes is abundant enough for 
progression to the metaphase-II stage.  
H89 acts as inhibitors of PKA and MSK1, whereas the activities of MSK1, 
RSKs, and PKC are predominantly inhibited by Ro31-8220 (Davies et al., 2000; 
Oh et al., 2010). PKA is thought to participate in meiotic arrest only at the 
prophase of meiosis I in the vertebrate oocytes (Perry and Verlhac, 2008). In this 
study, the abovementioned two inhibitors, H89 and Ro31-8220, induce to 
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release the metaphase-II arrest (Fig. 5). My data imply that at least MSK1 is 
involved in the metaphase-II arrest of mouse oocytes. This possibility appears to 
be supported by the fact that the RSK1/RSK2/RSK3 triple- and MSK1/MSK2 
double-knockout mice both display no overt phenotype (Dumont et al., 2005; 
Wiggin et al., 2002). Thus, I speculate that MSK1 and RSKs may serve as a 
compensatory mechanism to activate/phosphorylate EMI2 in the mouse oocytes 
(Fig. 9D).  
Both MSKs and RSKs are known to phosphorylate Ser/Thr residues in the 
conserved R/KXRXXS, RRXS, and RKS motifs (Hauge and Frodin, 2006). In 
some experiments, I examined whether mouse RSK1 possesses the ability to 
phosphorylate EMI2 (Fig. 11). My data demonstrated that MSK1 and RSK1 are 
both capable of directly phosphorylating S326, T327, S333, and S335 of mouse 
EMI2 (Figs. 7 and 11). When an EMI2/2A mutant carrying Ala substitutions at 
S326 and T327 was analyzed by in vitro kinase assays, MSK1 phosphorylated 
the Ser residues at positions 333 and 335 (Fig. 12). Since MSK1 fails to 
phosphorylate EMI2/4A mutant (Fig. 7E), either one or both of S333 and S335, 
in addition to S326 and T327, in the EMI2 molecule may be phosphorylated by 
MSK1. It is intriguing that the amino acid sequences carrying S333 and S335 
contain no consensus motifs of phosphorylation sites by MSKs. Thus, further 
experiments are required to elucidate the detailed mechanism on 
MSK1-catalyzed phosphorylation of EMI2.  
Since initial characterization of CSF (Masui and Markert, 1971), progress 
has been made in understanding the role of CSF in the oocytes at the molecular 
level. Recently, Xenopus Emi2 has been reported to be indispensable for the 
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Fig. 11. Phosphorylation of EMI2 by RSK1. (A) In vitro kinase assays for phosphorylation of EMI2 
by RSK1. GST-tagged EMI2 (1 μg) was incubated with purified RSK1 (0.1 μg, see Fig. 1) in the 
absence (0 μM) and presence of an RSK1 inhibitor, SL0101 (20 and 200 μM). Proteins were separated 
by SDS-PAGE and visualized by autoradiography and CBB staining. Data are presented as mean 
values ± S.E. (n = 3; *p<0.05). (B) In vitro kinase assays for phosphorylation of EMI2/4A by RSK1. 
Purified RSK1 was incubated with wild-type (WT) EMI2 or EMI2/4A (4A). GST was used as a 
negative control (-). Data are presented as mean values ± S.E. (n = 3; *p<0.05). 
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Fig. 12. Phosphorylation of EMI2/2A by MSK1. GST-tagged wild-type (WT) EMI2 and EMI2/2A (1 
μg) were incubated with purified MSK1 (0.1 μg) in the presence of [-32P]ATP, separated by 
SDS-PAGE, and analyzed by autoradiography and CBB staining. GST was used as a negative control 
(-). Data are presented as the mean values of two separate experiments. 
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CSF activity in the Mos–MAPK pathway (Inoue et al., 2007; Nishiyama et al., 
2007); the stabilization and activation of Emi2 are promoted by its 
phosphorylation catalyzed by RSKs. Because RSKs are not essential for the 
metaphase-II arrest in the mouse oocytes (Dumont et al., 2005), it has long been 
believed that other kinase(s) participates in phosphorylation of EMI2. My data 
presented here emphasize that MSK1 is a candidate protein involved in 
phosphorylation of EMI2. Thus, this study proposes a novel model for direct 
phosphorylation of EMI2 by MSK1 in the Mos–MAPK pathway of the mouse 
oocyte.  
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CHAPTER II 
 
 
p38 MAPK, in addition to the Mos-MAPK pathway, contributes to 
metaphase-II arrest through EMI2 phosphorylation in mouse oocytes 
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SUMMARY 
 
The Mos-MAPK signaling pathway involving the 
Mos-MEK1/2-ERK1/2-RSK1/2/3 or MSK1-EMI2 cascade is directly linked to 
metaphase-II arrest of vertebrate oocytes. Another kinase downstream of Mos 
has been postulated to participate in the oocyte arrest, because the metaphase-II 
arrest is not completely released by inhibition of MEK1/2. In this study, I 
examined whether p38, a member of the MAPK subfamily, is regulated under 
the control of Mos, and contributes to the metaphase-II arrest in the mouse 
oocyte. Morpholino oligonucleotide-mediated depletion of Mos revealed a 
remarkable decrease in phosphorylation of p38. Simultaneous treatment of 
oocytes with two chemical inhibitors of p38 and MEK1/2 induced both release 
from metaphase II and degradation of cyclin B1, whereas the treatment with 
each of these two inhibitors had little effect. Moreover, phosphorylation of 
EMI2 was dramatically abolished by addition of the two inhibitors. Indeed, 
MNK1, a kinase downstream of p38, exhibited the ability to phosphorylate 
EMI2. These results suggest that in addition to the Mos-MEK1/2 pathway, the 
Mos-mediated p38 pathway may be implicated in the metaphase-II arrest. 
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INTRODUCTION 
 
Vertebrate oocytes at the germinal-vesicle (GV) stage are arrested at 
prophase of meiosis I and undergo maturation after hormonal stimulation 
(Sagata, 1996; Kishimoto, 2003). Mature oocytes are rearrested at the metaphase 
of meiosis II until fertilization. The metaphase-II arrest is caused by the activity 
of cytostatic factor CSF (Masui and Markert, 1971) that inhibits the 
anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase 
required for degradation of cyclin B (Peters, 2006). As a consequence of cyclin 
B stabilization, the activity of MPF, the Cdk1-cyclin B complex (Gautier et al., 
1990), is maintained at an elevated level that prevents the exit from metaphase II 
and parthenogenetic activation of oocytes (Yamamoto et al., 2005). In Xenopus, 
CSF-mediated arrest involves the Mos-MAPK pathway 
(Mos-Mek1/2-Erk1/2-Rsk1/2/3) and Emi2, a direct inhibitor of the APC/C 
(Sagata et al., 1989; Gross et al., 2000; Dupré et al., 2002; Schmidt et al., 2005; 
Tung et al., 2005). Rsks phosphorylate four Ser/Thr residues of Emi2 at 
positions S335, T336, S342 and S344 (Inoue et al., 2007; Nishiyama et al., 
2007). Multiple phosphorylation of Emi2 upregulates its stability and inhibitory 
binding to the APC/C, thereby promoting the metaphase-II arrest (Wu et al., 
2007).  
In mice, the oocytes lacking Mos are activated without stimulation on 
fertilization (Colledge et al., 1994; Hashimoto et al., 1994; Araki et al., 1996; 
Choi et al., 1996; Verlhac et al., 1996). The EMI2-depleted oocytes sustain a low 
level of cyclin B after meiosis I, which leads to the failure to enter the 
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metaphase II (Madgwick et al., 2006; Shoji et al., 2006). Thus, both Mos and 
EMI2 are essential for the metaphase-II arrest in the oocytes, but the role of the 
components downstream of Mos is still controversial. Inhibition of MEK1/2 
synthesis by siRNA has little effect on the metaphase-II arrest (Yu et al., 2007). 
Injection of a constitutively active form of MEK1/2 into Mos-deficient oocytes 
fails to activate ERK1/2 (Verlhac et al., 2000). These findings raise the 
possibility that another Mos-dependent kinase also plays a key role in the 
metaphase-II arrest. 
p38 MAPK is one of the major members of the MAPK family that 
negatively regulates cell-cycle progression at both G1/S and G2/M in somatic 
cells (Thornton and Rincon, 2009). At least five Ser/Thr kinases, MSK1, MSK2, 
MNK1, MK2, and MK3, have been identified as p38 substrates (Cargnello and 
Roux, 2011). Functional analysis of p38 in the mouse oocytes suggests that this 
kinase regulates spindle assembly and accurate chromosome segregation 
through phosphorylation of MK2 (Yuan et al., 2010; Ou et al., 2010). 
In this study, I examined whether p38 is regulated under the control of Mos 
and contributes to the metaphase-II arrest in mouse oocytes. Depletion of Mos 
revealed a significant decrease in phosphorylation of p38. When the 
Mos-mediated MEK1/2 and p38 pathways were both blocked by specific 
inhibitors, the metaphase-II arrest was released. Possible role of p38 in the 
metaphase-II arrest is discussed.  
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MATERIALS AND METHODS 
 
All animal experiments performed ethically, and experimentation was in 
accord with the Guide for the Care and Use of Laboratory Animals at University 
of Tsukuba. 
 
Plasmids 
 
DNA fragments encoding EMI2 (Genbank ID: NP_001074772.1) and 
MSK1 (Genbank ID: AAQ24165.1) were amplified by polymerase chain 
reaction (PCR) using a mouse ovary or testis cDNA library as a template. 
Following sets of oligonucleotides were used as primers: 
5′-GGGCGGCCGCGGATGGACTCCTCTGCTGTC-3′ and 
5′-GGCTCGAGTCAGAGGCGTTTTAAGTTCCGC-3′ for EMI2; 
5′-GCCTCGAGAGGGTGAAGATGGAGGG-3′ and 
5′-GCTCTAGAACATACCTCAGGCACATG-3′ for MSK1. The amplified 
fragments were introduced into a pcDNA3/FLAG-HA vector. To prepare a 
pGEX4T-1/EMI2 plasmid containing the EMI2 sequence with residues 288-383, 
DNA fragments were PCR-amplified using pcDNA3/FLAG-HA/EMI2 as the 
template, and introduced into pGEX4T-1. A 
pcDNA3.1-poly(A)/FLAG-HA/EMI2 plasmid was prepared by introducing the 
KpnI/BamHI fragment of pcDNA3/FLAG-HA/EMI2 into pcDNA3.1-poly(A) as 
previously described (Yamazaki et al., 2007). In vitro site-directed mutagenesis 
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was carried out according to manufacturer’s protocol (Agilent Technology, Santa 
Clara, CA). 
 
Antibodies 
 
Synthetic phosphorylated peptide, Cys-Arg-Leu-Arg-Arg-Leu-phospho 
Ser-phospho Thr-Leu-Gln-Glu-Gln-Gly, corresponding to the 12-residues 
sequence of EMI2 at positions 321-332 was conjugated to maleimide-activated 
keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA) according 
to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA). The 
protein KLH-conjugated peptide was emulsified with Freund’s complete (Difco 
Laboratories, Detroit, MI) or incomplete adjuvant (Wako, Osaka, Japan), and 
injected into female Japanese white rabbits (Japan SLC, Shizuoka, Japan). 
Antibody against the unphosphorylated form of EMI2 was removed from serum 
using a Sepharose 4B column previously coupled with glutathione S-transferase 
(GST)-tagged EMI2 at residues 288-383. Anti-phosphorylated EMI2 antibody 
was purified using a Sepharose 4B column previously coupled with the 
BSA-conjugated 12-residue peptide. Anti-phosphorylated MNK1, 
anti-phosphorylated p38, and anti-phosphorylated ERK1/2 antibodies were 
purchased from Cell Signaling Technology (Danvers, MA), and anti-β-actin, 
anti-GAPDH, and fluorescein isothiocyanate (FITC)-conjugated anti-α-tubulin 
antibodies were from Sigma-Aldrich (Saint Louis, MO). Anti-cyclin B1, 
anti-HA and anti-Mos antibodies were purchased from Abcam (Cambridge, MA), 
Roche (Mannheim, Germany), and Santa Cruz Biotechnology (Santa Cruz, CA), 
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respectively. Horseradish peroxidase-conjugated antibodies against mouse, rat, 
or rabbit IgG were purchased from Jackson ImmunoResearch Laboratories 
(West Grove, PA). 
 
Oocyte collection and microinjection 
 
GV-stage oocytes were collected from ovaries of 6- to 9-week-old ICR mice 
(Japan SLC). The oocytes were placed in a drop of flushing-holding medium 
(FHM) containing 0.32 mM N
6
, 2′-O-dibutyryladenosine 3′:5′-cyclic 
monophosphate, dbcAMP (Sigma-Aldrich). The oocytes were microinjected 
with RNA samples (0.2 µg/µl), 4 mM morpholino oligonucleotide (MO; Gene 
Tools, Philomath, OR, see Table 1), or 50 mM small interfering RNA (siRNA; 
Sigma-Aldrich, see Table 1) using a FemtoJet constant flow system (Eppendorf, 
Hamburg, Germany). The oocytes were cultured in KSOM medium (SOM with 
a higher K
+
 concentration) containing 5% BSA at 37°C under 5% CO2 in air. 
 
Immunoblot analysis 
 
Proteins were separated by SDS-PAGE and transferred onto Immobilon-P 
polyvinylidene difluoride membranes (Millipore, Bedford, MA). The blots were 
blocked with 20 mM Tris-HCl, pH 7.5, containing 5% skim milk, 0.1% 
Tween-20, and 0.15 M NaCl, incubated with primary antibodies and then treated 
with secondary antibodies conjugated with horseradish peroxidase. The 
immunoreactive proteins were visualized using an ECL or ECL Prime Western   
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Blotting Detection kit (GE Healthcare, Piscataway, NJ). 
 
Immunostaining analysis 
 
Oocytes were fixed in phosphate-buffered saline (PBS) containing 4% 
paraformaldehyde at 4°C for 2 h, treated with 1% Triton X-100 in PBS for 20 
min, and blocked with PBS containing 1.5% goat serum and 0.05% Tween-20 at 
room temperature for 60 min. The oocytes were incubated with 
FITC-conjugated anti-α-tubulin antibody at room temperature for 60 min, 
counterstained with Hoechst 33342, and then viewed under an IX71 
fluorescence microscope (Olympus, Tokyo, Japan), as previously described 
(Kimura et al., 2009).  
 
RNA synthesis in vitro 
 
RNAs were synthesized by T7 polymerase using a RiboMAX Large Scale 
RNA Production System-T7 kit (Promega, Madison, WI). The synthesized 
RNAs were treated with RQ1 RNase-free DNase (Promega) at 37ºC for 20 min, 
extracted with phenol-chloroform, precipitated with ethanol, dissolved in 10 
mM Tris-HCl, pH 7.4, containing 0.1 mM EDTA, applied to MicroSpin G-25 
columns (GE Healthcare), and stored at -80°C.  
 
Immunoprecipitation 
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HEK293T cells were cultured in Dulbecco-modified Eagle medium 
supplemented with 10% fetal bovine serum, 100 U/ml of penicillin, and 0.1 
mg/ml of streptomycin at 37°C under 5% CO2 in air. Cells were transfected with 
expression plasmids encoding FLAG-HA-tagged MSK1, using a PerFectin 
transfection reagent (Genlantis, San Diego, CA). After 48 h, cells were cultured 
in serum-free medium for 24 h and then treated with 1 µM 
12-O-tetradecanoylphorbol-13-acetate (TPA; LC Laboratories, Woburn, MA) for 
60 min. Cells were lysed in a lysis buffer containing 25 mM Tris-HCl, pH 7.5, 
0.15 M NaCl, 0.1% SDS, 1% NP-40, 1 mM EDTA, 1 µg/ml aprotonin, 1 µg/ml 
pepstatin, 1 µg/ml leupeptin, 50 µg/ml PMSF, 1 mM DTT, 20 mM NaF, and 0.5 
mM Na3VO4. The cell lysates were subjected to immunoprecipitation using 
anti-FLAG M2-agarose beads (Sigma-Aldrich).  
 
RNA interference 
 
NIH3T3 cells were transfected with siRNA (0.1 µM) using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). After 24 h, cells were treated with 10 µM or 
0.5 mM H2O2 for 60 min for oxidative stress, and then lysed with the above lysis 
buffer. Proteins in the cell lysates were subjected to immunoblot analysis. 
 
In vitro kinase assay 
 
In vitro kinase assays were carried out in 10 mM Tris-HCl, pH 7.5, 
containing 10 mM MgCl2, 0.1 mM DTT, 2 mM Na3VO4, 50 µM NaF, and 0.2 
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mM ATP. GST-tagged EMI2 protein (1 µg) was incubated with MSK1 purified 
from HEK293T cells, MNK1 (Life Technologies, Carlsbad, CA), or MK2 (Enzo 
Life Sciences, Farmingdale, NY) in the above buffer at 30°C for 30 min, and 
analyzed by immunoblotting using anti-phosphorylated EMI2 antibody. 
 
Statistical analysis 
 
Data are presented as mean values ± S.E. (n = 3 or 4). The Student’s t-test 
was used for statistical analysis; significance was assumed for p < 0.05. 
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RESULTS 
 
Possible involvement of Mos in phosphorylation of p38  
 
I initially examined whether phosphorylation of p38 was affected by 
depletion of Mos. Since MO is known to effectively induce Mos reduction 
(Coonrod et al., 2001), GV-stage oocytes were injected with 4 mM MO against 
Mos mRNA (Mos/MO) or 4 mM negative control MO (Control/MO) in FHM 
containing dbcAMP. After 2-h incubation, the oocytes were cultured in KSOM 
medium in the absence of dbcAMP for 16 h. Depletion of Mos was verified by 
immunoblot analysis (Fig. 13A). Importantly, phosphorylation of both ERK1/2 
and p38 was remarkably decreased in the Mos-depleted oocytes. 
Immunostaining analysis indicated that approximately 70% of the 
Control/MO-injected oocytes were arrested at metaphase II, whereas a 
significantly low proportion (15%) of the metaphase-II oocytes was found in the 
Mos/MO-injected oocytes (Fig. 13B). Since almost 60% of the 
Mos/MO-injected oocytes contained large polar bodies or decondensed 
chromatin formation, as described previously (Coonrod et al., 2001), the oocytes 
exhibiting abnormal cell divisions were classified into other cell-cycle stage. 
These results suggest that Mos may be involved in the phosphorylation state of 
p38, and imply that p38 may partly participate in the metaphase-II arrest.  
 
p38 contributes to metaphase-II arrest  
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Fig. 13. Possible involvement of Mos in phosphorylation of p38. (A) Depletion of Mos by injection 
with morpholino oligonucleotide (MO). The germinal vesicle (GV)-stage oocytes were injected with 4 
mM MO against Mos mRNA (Mos/MO) or negative control MO (Control/MO), and incubated in the 
presence of dbcAMP. After 2-h incubation, the oocytes were cultured in the absence of dbcAMP for 16 
h. Whole protein extracts of the MO-injected oocytes (30 cells/lane) were analyzed using antibodies 
against Mos, phosphorylated ERK1/2 (pERK1/2), phosphorylated p38 (pp38), and GAPDH. (B) 
Immunostaining analysis. The injected oocytes were stained with α-tubulin (green) and Hoechst 33342 
(blue). The ratio of oocytes at the GV, metaphase I (MI), metaphase II (MII), and other stages was 
counted.  
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To test the possibility that a p38 pathway functions in metaphase-II arrest, I 
examined the effect of U0126 and SB203580 (Favata et al., 1998; Frantz et al., 
1998) that specifically interfere with the activity of MEK1/2 and p38, 
respectively (Fig. 14). Themetaphase-II oocytes were incubated with 20 µM 
U0126 and/or 60 µM SB203580 for 7 h, and subjected to immunostaining 
analysis (Fig. 14A). SB203580 had little effect on the metaphase-II arrest (Fig. 
14B). Approximately 20% of the U0126-treated oocytes exhibited cell-cycle 
resumption, and the remainder (~80%) maintained the arrest with shrinking 
bipolar spindle. The simultaneous treatment with U0126 and SB203580 led to 
chromosome segregation, a hallmark of anaphase progression (~90% of the total 
oocytes). Although the level of cyclin B1 slightly decreased in the presence of 
U0126 or SB203580, simultaneous treatment dramatically induced degradation 
of cyclin B1 (Fig. 14C). Moreover, the phosphorylation state of ERK1/2 was not 
affected by SB203580, as expected. Thus, the p38 pathway, in addition to the 
Mos-MAPK pathway, may contribute to the maintenance of metaphase-II arrest.  
 
Phosphorylation of EMI2 in mouse oocytes 
Xenopus Emi2 is activated and stabilized by phosphorylation at S335, T336, 
S342 and S344 during meiosis II (Inoue et al., 2007; Nishiyama et al., 2007). 
These four Ser/Thr residues are evolutionarily well conserved in the mouse, 
human, and zebrafish counterparts (Fig. 15A). To examine phosphorylation of 
EMI2 by the p38 pathway, I prepared anti-phosphorylated EMI2 antibody that 
recognizes phosphorylated S326 and T327 of mouse EMI2. The antibody 
specificity was validated by in vitro kinase assays using MSK1 purified from  
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Fig. 14. p38 contributes to metaphase-II arrest. (A) Immunostaining analysis. The metaphase-II 
oocytes were incubated in the absence (−) or presence (+) of 60 µM SB203580 and 20 µM U0126 for 
7 h and stained with anti-α-tubulin antibody (green) and Hoechst 33342 (blue). (B) The effect of 
SB203580 and U0126 on metaphase-II release. The metaphase-II oocytes were incubated in the 
absence (−) or presence (+) of 60 µM SB203580 and 20 µM U0126 for 7 h. The ratio of oocytes 
released from metaphase-II arrest was counted (*p<0.05). (C) Immunoblot analysis. The metaphase-II 
oocytes were incubated with (+) or without (−) 60 µM SB203580 and 20 µM U0126 for 7 h. Whole 
protein extracts (30 cells/lane) were analyzed using anti-cyclin B1 (CycB1), anti-phosphorylated 
ERK1/2 (pERK1/2), and anti-GAPDH antibodies. 
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Fig. 15. Phosphorylation of EMI2 in mouse oocytes. (A) Alignment of the amino acid sequences of 
EMI2 among mouse, human, Xenopus, and zebrafish. Black boxes indicate the conserved residues. 
S326, T327, S333, and S335 of mouse EMI2 are phosphorylated by MSK1 and RSKs. The sequence 
of an EMI2/2A mutant is also aligned. (B) In vitro kinase assay. GST-tagged EMI2 was incubated with 
(+) or without (−) 100 ng purified MSK1, treated with (+) or without (−) lambda protein phosphatase 
(pp), and subjected to immunoblot analysis using anti-phosphorylated EMI2 (pEMI2) and anti-GST 
antibodies. (C) Recognition of EMI2/2A by anti-pEMI2 antibody. GST-tagged wild-type EMI2 (WT) 
or EMI2/2A (2A) was incubated with (+) or without (−) MSK1. (D) Phosphorylation of EMI2 in 
mouse oocytes. The GV-stage oocytes were injected with (+) polyadenylated RNA encoding 
HA-tagged EMI2/DSG or were not injected (−); these oocytes were cultured for 12 h. The injected 
oocytes (15 cells/lane) were subjected to immunoblot analysis using antibodies against pEMI2, HA, 
and GAPDH. 
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HEK 293T cells and GST-fused protein containing the amino acid sequence of 
EMI2 at positions 288-383. Consistent with the fact that MSK1 phosphorylates 
S326, T327, S333, and S335 in the EMI2 peptide (Miyagaki et al., 2011), 
MSK1-phosphorylated EMI2 was recognized by anti-phosphorylated EMI2 
antibody (Fig. 15B). No protein was immunoreactive with anti-phosphorylated 
EMI2 antibody, when phosphorylated EMI2 was treated with lambda protein 
phosphatase (Fig. 15B), and when a GST-fused EMI2 mutant protein, EMI2/2A, 
in which S326 and T327 are substituted with Ala (Miyagaki et al., 2011), was 
analyzed by in vitro kinase assays (Fig. 15C). Thus, this antibody recognizes 
S326- and T327-phosphorylated EMI2. To ascertain phosphorylation of EMI2 in 
mouse oocytes, I carried out immunoblot analysis of metaphase-II oocytes using 
anti-phosphorylated EMI2 antibody. However, no phosphorylated EMI2 
immunoreactive with the antibody was found when 50 metaphase-II oocytes 
were examined (data not shown). The reason may be due to a very low 
abundance of EMI2 in the metaphase-II oocytes. I thus injected RNA encoding 
an HA-tagged EMI2 mutant, EMI2/DSG (Miyagaki et al., 2011), into GV-stage 
oocytes, because the mutant protein is thought to be resistant to a 
ubiquitin-mediated proteolysis (Shoji et al., 2006). The EMI2/DSG-injected 
oocytes were cultured for 12 h and subjected to immunoblot analysis (Fig. 15D). 
The exogenous phosphorylated EMI2 was detected as a 90-kDa protein. These 
results suggest that the mouse oocytes possess an effective tool for 
phosphorylation of EMI2.  
 
Phosphorylation of EMI2 by the p38 pathway 
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At least five Ser/Thr kinases have been identified as substrates of p38 
(Cargnello and Roux, 2011). I speculated that these five kinases are involved in 
phosphorylation of EMI2. To ask whether EMI2 is targeted by the p38 pathway 
in the CSF arrest, HA-tagged EMI2/DSG RNA was injected into GV-stage 
oocytes in the presence of dbcAMP. The EMI2/DSG-injected oocytes were then 
cultured in the absence of dbcAMP for 12 h, and the oocytes were further 
transferred to a medium containing U0126 and/or SB203580 (Fig. 16A). 
SB203580 had little effect on phosphorylation of EMI2, whereas EMI2 
phosphorylation was approximately 30% inhibited by the presence of U0126 
(Fig. 16B). A significantly great reduction (~70%) of EMI2 phosphorylation was 
induced by simultaneous treatment with U0126 and SB203580. Thus, EMI2 
phosphorylation may be coregulated by the p38 pathway, in addition to the 
MEK1/2 pathway. Exogenously expressed Emi2 in the GV-stage oocytes is 
known to induce the metaphase-I arrest under the above conditions (Suzuki et al., 
2010; Miyagaki et al., 2011). To examine whether the metaphase-I arrest is 
released by kinase inhibitors, I performed immunostaining analysis of 
inhibitor-treated oocytes (Fig. 16C). The bipolar spindle with chromosome 
alignment was normally observed after the treatment with each of U0126 and 
SB203580, indicating the maintenance of metaphase-I arrest. Despite 
significantly reduced phosphorylation of EMI2, the oocytes treated with both 
U0126 and SB203580 underwent no chromosome segregation but contained 
irregularly scattered chromosomes.  
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Fig. 16. p38 pathway is involved in phosphorylation of EMI2. (A) Experimental protocol for 
expression of HA-tagged EMI2/DSG mutant. The germinal vesicle (GV)-stage oocytes were injected 
with polyadenylated RNA encoding HA-tagged EMI2/DSG in the presence of dbcAMP and cultured 
in the absence of dbcAMP for 12 h. After 12 h of culture, the oocytes were incubated in the presence 
of kinase inhibitors for 6 h. GVBD, GV breakdown. (B) Immunoblot analysis. The injected oocytes 
were incubated in the absence (−) or presence (+) of 60 µM SB203580 and 20 µM U0126 for 6 h. The 
whole protein extracts (30 cells/lane) were subjected to immunoblot analysis using antibodies against 
phosphorylated EMI2 (pEMI2) and HA. Chemiluminescence intensity of pEMI2 was measured and 
corrected by HA intensity (*p<0.05). (C) Immunostaining analysis. The injected oocytes were 
incubated with (+) or without (−) 60 µM SB203580 and 20 µM U0126 for 6 h, stained with 
anti-α-tubulin antibody (green) and counterstained with Hoechst 33342 (blue). 
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Direct phosphorylation of EMI2 by MNK1 
 
Since MNK1 and MK2 as substrates of p38 are activated during oocyte 
maturation (Ellederová et al., 2008; Yuan et al., 2010), I asked if these two 
kinases directly phosphorylate EMI2. In vitro kinase assays indicated that both 
MNK1 and MK2 are capable of phosphorylating EMI2 (Figs. 17A and 17B). I 
also examined the effects of two kinase inhibitors, CGP57380 and CMPD1, on 
the phosphorylation state of EMI2 in mouse oocytes (Fig. 17C). CGP57380 is 
known to inhibit the activity of MNK1 and exhibit no inhibitory effect on p38 
and ERK1/2 (Knauf et al., 2001). On the other hand, p38-catalyzed 
phosphorylation of MK2 is inhibited by CMPD1 in a non-ATP-competitive 
manner; this inhibitor specifically blocks the p38 activity toward MK2 
(Davidson et al., 2004). The GV-stage oocytes were injected with HA-tagged 
EMI2/DSG RNA, matured to the metaphase-I stage, and then incubated in the 
presence of 20 µM U0126 and 60 µM CGP57380 or 60 µM CMPD1 for 6 h. 
HA-tagged EMI2 remained phosphorylated in the oocytes treated with U0126 
and CMPD1, whereas the treatment with both U0126 and CGP57380 inhibited 
phosphorylation of EMI2. Moreover, CGP57380 alone had little effect on 
phosphorylation of EMI2 (Fig. 18). These data suggest that MNK1, in addition 
to other kinases downstream of MEK1/2, phosphorylates EMI2 during the CSF 
arrest. Phosphorylation of MNK1 at positions T197 and T202 by ERK1/2 and 
p38, respectively, are required for the activity of MNK1 in somatic cells 
(Fukunaga and Hunter, 1997; Waskiewicz et al., 1997). I examined whether 
MNK1 phosphorylation in the oocytes depends on ERK1/2 and p38. When the  
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Fig. 17. Direct phosphorylation of EMI2 by MNK1. (A and B) In vitro kinase assays for 
phosphorylation of EMI2 by MNK1 and MK2. GST-tagged EMI2 was incubated with (+) or without 
(−) 350 ng MNK1 or 100 ng MK2 and subjected to immunoblot analysis using anti-phosphorylated 
EMI2 (pEMI2) and anti-GST antibodies. (C) Effect of CMPD1 and CGP57380 on EMI2 
phosphorylation in the oocytes. The germinal vesicle (GV)-stage oocytes were injected with RNA 
encoding HA-tagged EMI2/DSG in the presence of dbcAMP and cultured in the absence of dbcAMP 
for 12 h. The oocytes (30 cells/lane) were incubated in the absence (−) or presence (+) of 60 µM 
CMPD1, 60 µM CGP57380, or 20 µM U126 and were subjected to immunoblot analysis using 
antibodies against pEMI2 and HA. (D) The effect of SB203580 and U0126 on the phosphorylation of 
MNK1. The metaphase-II oocytes (30 cells/lane) were incubated with (+) or without (−) 60 µM 
SB203580 and 20 µM U0126 for 7 h and subjected to immunoblot analysis using anti-phosphorylated 
MNK1 (pMNK1), anti-cyclin B1 (CycB1), and anti-GAPDH antibodies. (E) Mos regulates 
phosphorylation of MNK1. The GV-stage oocytes were injected with 4 mM morpholino 
oligonucleotide (MO) against Mos mRNA (Mos/MO) or negative control MO (Control/MO) and 
incubated in the presence of dbcAMP. After 2-h incubation, the oocytes (30 cells/lane) were cultured 
in the absence of dbcAMP for 16 h and subjected to immunoblot analysis using anti-pMNK1 and 
anti-GAPDH antibodies.  
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metaphase-II oocytes were treated with both SB203580 and U0126 for 6 h, the 
level of phosphorylated MNK1 was remarkably decreased (Fig. 17D). The 
injection of Mos/MO into the GV-stage oocytes also induced downregulation of 
phosphorylated MNK1 (Fig. 17E).  
Thus, phosphorylation of MNK1 may be regulated by the Mos-MAPK and 
p38 MAPK pathways in the metaphase-II oocytes.  
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Fig. 18. Effect of CGP57380 on phosphorylation state of EMI2. The germinal vesicle (GV)-stage 
oocytes were injected with RNA encoding HA-tagged EMI2/DSG in the presence of dbcAMP. The 
injected oocytes were cultured for 12 h in the absence of dbcAMP and incubated with (+) or without 
(−) 60 µM CGP57380 and 20 µM U0126 for 6 h. Whole protein extracts (30 cells/lane) were subjected 
to immunoblot analysis using anti-phosphorylated EMI2 (pEMI2) and anti-HA antibodies. 
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DISCUSSION 
 
This study reveals that p38 plays an important role in EMI2-mediated 
metaphase-II arrest in the mouse oocytes. Although Mos activates MEK1/2 
during oocyte maturation (Nebreda and Hunt, 1993; Posada et al., 1993; Shibuya 
and Ruderman, 1993), Mos has been postulated to inhibit the activity of an 
unknown phosphatase (Verlhac et al., 2000). As shown in Fig. 13A, the 
inhibition of Mos synthesis results in the failure of p38 phosphorylation, 
suggesting that Mos may regulate phosphorylation of p38. Activation of p38 
requires phosphorylation at T180 and Y182 in Thr-Gly-Tyr motif by MKK3/6 
(Raingeaud et al., 1995; Enslen et al., 2000). It is unlikely that Mos directly 
phosphorylates p38 in the metaphase-II oocytes, because Mos is a Ser/Thr 
kinase incapable of phosphorylating Y182 in p38. Thus, I assume that 
phosphorylation of p38 is regulated by a Mos-mediated phosphatase, or that 
Mos regulates a kinase(s) upstream of p38. 
The metaphase-II arrest was released by inhibition of MEK1/2 and p38 (Fig. 
14B). Inhibition of each kinase activity was insufficient to exit from metaphase 
II, implying the presence of a compensatory mechanism. Since the 
MEK1/2-depleted oocytes develop to metaphase II and maintain the 
metaphase-II arrest (Yu et al., 2007), the p38 pathway may compensate for 
phosphorylation of EMI2 in the MEK1/2-depleted oocytes. Approximately 20% 
of the oocytes treated with U0126 were released from the metaphase-II arrest, 
whereas SB203580 had little effect (Fig. 14B). These results suggest that 
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phosphorylation of EMI2 may be regulated more predominantly by the 
Mos-MAPK pathway than by the p38 pathway.  
The simultaneous treatment with U0126 and SB203580 induced ~70% 
reduction in phosphorylation of EMI2 in the metaphase I-arrested oocytes (Fig. 
16B). Unexpectedly, the metaphase-I arrest was maintained in the presence of 
these two inhibitors, despite the remarkable decrease in EMI2 phosphorylation 
(Fig. 16C). The maintenance of metaphase-I arrest may be due to the possibility 
that a relatively low level (~30%) of phosphorylated EMI2 may be enough to 
interfere with the cell-cycle resumption. Moreover, the metaphase I-arrested 
oocytes displayed the abnormality in spindle formation and chromosome 
alignment in the presence of both SB203580 and U0126 (Fig. 16C). These 
results suggest that in addition to phosphorylation of EMI2, MEK1/2 and p38 
may have other unique functions. Mos is indispensable for activation of MISS 
and DOC1R that are localized at the metaphase spindle and are involved in 
spindle formation (Lefebvre et al., 2002; Terret et al., 2003). My data revealed 
that phosphorylated p38 is colocalized with α-tubulin at the metaphases I and II 
(Fig. 19). Thus, the p38 pathway as well as the Mos-MAPK pathway may be 
implicated in spindle formation through activation of MISS and DOC1R. 
It has been reported that phosphorylated MK2 is present during oocyte 
maturation, and CMPD1 (30 µM) is sufficient to inhibit the activity of MK2 in 
mouse oocytes (Yuan et al., 2010). I found that although MK2 phosphorylates 
EMI2 in vitro (Fig. 5B), EMI2 in mouse oocytes is barely phosphorylated even 
in the presence of 60 µM CMPD1 (Fig. 17C). Thus, EMI2 phosphorylation may 
be unaffected by MK2 in the CSF-arrested oocytes. Further experiments are   
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Fig. 19. Localization of phosphorylated p38 during oocyte maturation. Immunostaining analysis. The 
germinal vesicle (GV)-, prometaphase I (Pro-MI)-, metaphase I (MI)-, and metaphase II (MII)-stage 
oocytes were stained with anti-phosphorylated p38 (pp38, red) and FITC-conjugated anti-α-tubulin 
(green) antibodies and counterstained with Hoechst 33342 (blue). 
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required to elucidate the functional difference of MK2 between in vitro and in 
vivo. 
To clarify the role of p38 and ERK1/2 in establishing the metaphase-II 
arrest, I designed siRNAs against the three mRNAs (Table 1). The levels of 
phosphorylated p38, ERK1, and ERK2 were 70~85% decreased by introduction 
of the siRNAs into NIH3T3 cells (Fig. 20A). In the mouse oocytes, the levels of 
these three kinases were unchanged by the siRNA injection (Fig. 20B). siRNA 
knockdown of Mos and EMI2 was enough to interfere with normal maturation 
of oocytes (Figs. 13 and 21). p38 and ERK1/2 are already present in the 
GV-stage oocytes (Ou et al., 2010; Verlhac et al., 1993), whereas Mos and EMI2 
are synthesized after GV-breakdown and metaphase-I stages, respectively 
(Paules et al., 1989; Madgwick et al., 2006). I thus speculate that proteins 
already present at the GV stage are not efficiently reduced by the siRNA 
injection into the oocytes. 
Mos has been demonstrated to trigger the MEK1/2-ERK1/2 cascade 
(Nebreda and Hunt, 1993; Posada et al., 1993; Shibuya and Ruderman, 1993). 
My results suggest that Mos may function in phosphorylation of p38 involved in 
activation of EMI2 through phosphorylation of MNK1. I have previously 
reported the functional redundancy of MSK1 and RSKs in EMI2 
phosphorylation (Miyagaki et al., 2011). Since MNK1 is one of kinases that 
participate in phosphorylation of EMI2, the MEK1/2-ERK1/2-RSK1/2/3 or 
MSK1-EMI2 and p38-MNK1-EMI2 cascades governed by Mos may mediate 
the metaphase-II arrest in the mouse oocytes. 
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Fig. 20. RNA interference for Erk1, Erk2, and p38. (A) I designed three different sequences of small 
interfering RNA (siRNA) against each mRNA, Erk1, Erk2, and p38 (ERK1-1/2/3, ERK2-1/2/3, and 
p38-1/2/3). NIH3T3 cells were transfected with the siRNAs or negative control (Control). After 24 h 
of culture, cells were incubated in the presence of 10 µM or 0.5 mM H2O2 for 60 min and subjected to 
immunoblot analysis using anti-phosphorylated ERK1/2 (pERK1/2), anti-phosphorylated p38 (pp38), 
and anti-GAPDH antibodies. (B) The germinal vesicle (GV)-stage oocytes were injected with a 
mixture of ERK1-1 and ERK2-3, p38-3, or Control and incubated in the presence of dbcAMP for 24 h. 
The injected oocytes were cultured in the absence of dbcAMP for 16 h and subjected to immunoblot 
analysis using antibodies against pERK1/2, pp38, and GAPDH. 
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Fig. 21. EMI2 depletion by injection with morpholino oligonucleotide (MO). The germinal vesicle 
(GV)-stage oocytes were injected with 4 mM MO against Emi2 mRNA (EMI2/MO) or negative 
control MO (Control/MO) and incubated in the presence of dbcAMP for 2 h. The oocytes were then 
cultured in the absence of dbcAMP for 16 h and subjected to immunostaining analysis using 
FITC-conjugated anti-α-tubulin antibody (green) and Hoechst 33342 (blue). The ratio of oocytes at the 
GV, metaphase I (MI), metaphase II (MII), and other stages was counted. 
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GENERAL CONCLUSION 
 
This study raises the possibility that MSK1 and p38 contribute to 
maintenance of metaphase-II arrest in the mouse oocytes. 
The chapter I describes the possible role of MSK1 in the oocytes. MSK1 
was present during oocyte maturation, and was phosphorylated at the 
metaphase-I and metaphase-II stages (Figs. 2 and 10). Phosphorylated MSK1 
exhibited the ability to phosphorylate EMI2 in vitro (Fig. 7). In addition, the 
treatment of metaphase II-arrested oocytes with the inhibitor of MSK1 released 
the oocytes from the metaphase-II stage (Fig. 5). Thus, MSK1 may play a key 
role in the metaphase-II arrest through phosphorylation of EMI2. In the chapter 
II, I examined whether p38 is regulated under the control of Mos and has a role 
in the metaphase-II arrest. Since phosphorylation of p38 was abolished by 
depletion of Mos (Fig. 13), Mos may be involved in p38 phosphorylation. 
Interestingly, the treatment of oocytes with the inhibitors of p38 and MEK1/2 
revealed a remarkable decrease in phosphorylation of EMI2, and induced 
activation of metaphase-II oocytes (Figs. 14 and 16). These results suggest that 
the p38 pathway, in addition to the MEK1/2 pathway, may be implicated in the 
metaphase-II arrest. On basis of these data obtained, I propose a schematic 
model for phosphorylation of EMI2 (Fig. 22). Although Mos triggers the 
MEK1/2-ERK1/2 cascade (Nebreda and Hunt, 1993; Posada et al, 1993; 
Shibuya and Runderman, 1993), my results suggest that Mos may be involved in 
phosphorylation of p38 as well as MEK1/2. Moreover, it is most likely that 
MSK1 and MNK1 both contribute to phosphorylation of EMI2. 
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Fig. 22. A Schematic model for metaphase-II arrest in mouse oocytes. Mos may regulate the 
phosphorylation state of p38 as well as MEK1/2. In addition to RSKs, two Ser/Thr kinases, MSK1 and 
MNK1, are capable of phosphorylating EMI2. Thus, Mos governs at least two signaling pathways: 
MEK1/2 and p38 pathways. 
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Parthenogenetic activation of mouse oocytes has been suggested to result in 
development of ovarian teratomas (Eppig et al, 1977). Indeed, ovarian tumors 
develop in the Mos-defficient mouse (Furuta et al, 1995). Thus, this study will 
provide a clue to elucidate the mechanism of ovarian tumorigenesis.  
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